Encepheal Therapeutics
EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examp
Y Combinator
yc-company-directory #1604EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examp
sourceEncepheal Therapeutics is classified as Healthcare from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Encepheal Therapeutics
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Altay Therapeutics
match 68Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affe
shared product terms: develop, small, molecule, treat; same category: Healthcare; shared affiliation: Y Combinator
Serna Bio
match 53Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.
shared extracted concept terms: small, molecule; shared product terms: develop, treat, small, molecule; shared affiliation: Y Combinator
Osmind
match 41Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science
shared product terms: medication, there, fda, treatment; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Eris Biotech
match 41We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
shared product terms: develop, small, molecule, therapeutic; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
XGenomes
match 33At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix c
shared product terms: molecule, there, no, directly; shared affiliation: Y Combinator
Matrubials
match 33Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk
shared product terms: molecule, therapeutic, treatment; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator